^
    15h
    A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze) (clinicaltrials.gov)
    P2, N=150, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Dec 2029 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    17h
    A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, West China Hospital
    New P2 trial • Checkpoint inhibition
    |
    Anniko (penpulimab-kcqx) • Meiyouheng (becotatug vedotin) • Yidafan (ivonescimab) • becotarug (JMT101)
    1d
    Solitary Fibrous Tumor of the Oropharyngeal Lateral Wall: A Case Report and Review of Diagnostic and Therapeutic Challenges. (PubMed, Cureus)
    This report highlights the challenges in diagnosing and treating oropharyngeal SFTs. It emphasizes the need for molecular confirmation and adds to the limited research on SFTs in rare head and neck locations.
    Journal
    |
    STAT6 (Signal transducer and activator of transcription 6)
    1d
    Comparative study on salivary IL- 8 and LDH among tobacco users without lesions, leukoplakia, oral submucous fibrosis and oral squamous cell carcinoma. (PubMed, Bioinformation)
    40 cases were analysed in this study. We show that salivary IL8 and LDH which can serve as one reliable biomarker in early detection of OSCC and a prognostic indicator for OPMDs.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    3d
    Observational Study of Objective Response Rate to Ivonescimab Combined with Chemotherapy in Patients with Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma (ChiCTR2600117410)
    P=N/A, N=20, Not yet recruiting, Zhujiang Hospital of Southern Medical University; Zhujiang Hospital of Southern Medical University
    New trial
    |
    Yidafan (ivonescimab)
    3d
    The Efficacy of Electrical Acupoint Stimulation Based on Syndrome Differentiation and Treatment on Chemotherapy-Induced Myelosuppression in Patients with Oral and Maxillofacial Tumors (ChiCTR2600116779)
    P=N/A, N=122, Recruiting, Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Ninth People's Hospital Affiliated to Shanghai Jiao Tong Unive
    New trial
    3d
    A Prospective, Single-Arm, Phase II Clinical Study of Nimotuzumab Combined with Tislelizumab as Neoadjuvant Therapy for Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma Who Are Intolerant to Platinum-Based Chemotherapy (ChiCTR2600116769)
    P4, N=48, Not yet recruiting, Beijing Cancer Hospital; Beijing Cancer Hospital
    New P4 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    EGFR positive
    |
    Tevimbra (tislelizumab-jsgr) • TheraCIM (nimotuzumab)
    3d
    Radiotherapy combined with nimotuzumab versus radiotherapy alone in patients with platinum-intolerant locally advanced head and neck squamous cell carcinoma (ChiCTR2500114545)
    P3, N=335, Not yet recruiting, Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    TheraCIM (nimotuzumab)
    3d
    A single-arm, open-label, single-center clinical study on neoadjuvant therapy of chemotherapy combined with target immunotherapy before surgery for local advanced oral squamous cell carcinoma (ChiCTR2600116229)
    P2, N=44, Not yet recruiting, The First Affiliated Hospital of Sun Yat-sen University; The First Affiliated Hospital of Sun Yat-sen University
    New P2 trial
    3d
    A prospective, single arm, phase II clinical study of nimotuzumab combined with concurrent radiotherapy in the treatment of moderate risk patients after head and neck squamous cell carcinoma surgery (ChiCTR2500112384)
    P2, N=63, Not yet recruiting, Tianjin Cancer Hospital; Tianjin Cancer Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    Erbitux (cetuximab) • TheraCIM (nimotuzumab)
    5d
    Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survival Trial (clinicaltrials.gov)
    P=N/A, N=643, Completed, Rutgers, The State University of New Jersey | Trial completion date: Apr 2025 --> Dec 2025 | Trial primary completion date: Jan 2025 --> Aug 2025
    Trial completion date • Trial primary completion date
    6d
    First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients (clinicaltrials.gov)
    P2, N=32, Recruiting, Wake Forest University Health Sciences | Trial completion date: Aug 2027 --> Aug 2028 | Trial primary completion date: Jan 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel